FINISTERRAE means “the end of the world”. In our case, it is referred to genomic and biomedical Big Data principles with translational means. Our goal is to make big data smaller, completely reducing its complex nature. ... making it easier to find new therapeutic targets and orphan drugs for rare diseases. ...and also in neurodegenerative diseases (Parkinson, Alzheimer, ALS,...) and Cancer. Contact: Juan Luis Fernández Martínez. Inverse Problems Group jlfm@uniovi.es | +34 682202198 Ignacio Fdez. Alberti. Salud Social Media ignacioalberti@saludsocialmedia.com

1. effective analysis of biomedical BIG DATA
the optimization of drugs for rare and
neurodegenerative diseases, and cancer

2. FINISTERRAE

3. FINISTERRAE
Big Data for the
optimization of drugs for
rare and neurodegenerative
diseases, and Cancer.
“This generation has a historic opportunity
and responsibility to transform medicine by
using systematic approaches in the
biological sciences to dramatically
accelerate the understanding and
treatment of disease”
The Eli and Edythe L. Broad Institute
Of MIT and Harvard

4. FINISTERRAE
means “the end of the
world”. In our case, it is
referred to genomic and
biomedical BIG DATA
principles with
translational means. Our
goal is to make big data
smaller, completely
reducing its complex
nature.

5. ... making it easier
to find new
therapeutic targets
and orphan drugs
for RARE DISEASES.

6. ...and also in
neurodegenerative
diseases
(Parkinson,
Alzheimer, ALS,...)
and Cancer.

7. What’s more, we want to
make early diagnosis of
various types of CANCER
more accurate, as well as
make the optimization of
personalized treatment
possible (precision
translational medicine)

8. Also, the
FINISTERRAE
platform will
contribute to the
OPTIMIZATION OF
MEDICAL DECISIONS
and the providing
additional value to
hospital data.

9. Regarding drug optimization, SECONDARY EFFECTS
MINIMIZATION would be very interesting so that patients do
not have to go through unnecessary suffering.

10. LET’S TALK
NUMBERS

11. 7000: number of RARE
DISEASES that affect over
30 million people in the
USA and some more in
Europe. Over the past
few years, small
pharmaceutical
companies have
launched various dozens
of drugs.

12. NEURODEGENERATIVE
DISEASES are one of the
biggest issues of today’s
society. By itself,
Alzheimer affects more
than 7 million Europeans,
and it is thought that this
number will be
duplicated in less than
20 years.

13. Despite all the billions
of dollars invested in
CANCER investigation,
the obtained results for
preventing it and for
carrying out advanced
treatments are highly
disappointing.

14. Only 500 out of 10.000
drugs found in
investigation period
pass on to preclinical
period, and from there
only 1 of them goes on
to clinical use.
www.acrohealth.org

15. BREAST
CANCER

16. MAMMAPRINT
ONCOTYPE
MAMMOSTRAT are
really expensive,
although trustworthy
tests
possible metastasis
prediction during
diagnosis

17. The goal is to come up with
simple, solid, trustworthy and
non-expensive methods to
ameliorate diagnosis and
Breast Cancer treatment,
significantly reducing
mortality.

18. And this
methodology
can also be
applied to
other types of
CANCER:
COLORECTAL,
LUNG,
PROSTATE,
PANCREAS…

22. We model biomedical data
and we obtain information
that would be impossible to
find using traditional
methods. We are opened for
proofs of concepts to show
our capabilities.
We work using a win-win
methodology.

23. S O M E F I NIST E R R A E’S
R E F E R E N C E S

28. S O M E F I NIST E R R A E’S
R E S U LT S

29. CORRELATION NETWORK for
CHRONIC LYMPHOCITIC LEUKEMIA (CLL)

30. Main Mutations in
CLL and how they
impact expression

31. CORRELATION NETWORK for MYOSITIS

32. CORRELATION NETWORK for ALS

33. • We have found very innovative
results about the disease
mechanisms in Alzheimer,
Parkinson, ALS and Multiple
Sclerosis, for instance.
• We are modelling different rare
diseases that have genetic data
available in public data
repositories.
• We are able to fusion different
kind of data for Treatment
Optimization.

34. Ignacio Fdez.-Alberti
IIRR and Corporate
Communications
Juan Luis Fdez.-
Martínez
Professor in Applied
Mathematics.
CTO.
Zulima Fernández-
Muñiz
PhD in Applied
Mathematics.
Ana Cernea-Cobernau
PhD in Applied
Mathematics.
Enrique J. De Andrés
Galiana
PhD in Applied
Mathematics.
The TEAM

35. Juan Luis Fernández Martínez
Inverse Problems Group
jlfm@uniovi.es
+34 682202198
Ignacio Fdez. Alberti
Salud Social Media
ignacioalberti@saludsocialmedia.com
CONTACT TO
DISCOVER NEW
OPPORTUNITIES